GMABGenmab A/S
$37.06+31% 1Y
$37.06
$23.8552 weeks$38.47
GMAB as reported
- Operating margin
- 25%
Operating margin · trailing twelve months to Q2 2024
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Gross margin | 96% | n/a | Q2 2024 |
| Operating margin | 25% | n/a | Q2 2024 |
| Net margin | 29% | n/a | Q2 2024 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Genmab A/S (GMAB) · Revenue and profitRevenue and profitGenmab A/S (GMAB)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
